Literature DB >> 16885372

Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.

Tonya C Walser1, Salah Rifat, Xinrong Ma, Namita Kundu, Chris Ward, Olga Goloubeva, Michael G Johnson, Julio C Medina, Tassie L Collins, Amy M Fulton.   

Abstract

Tumor cells aberrantly express chemokines and/or chemokine receptors, and some may promote tumor growth and metastasis. We examined the expression and function of chemokine receptor CXCR3 in a syngeneic murine model of metastatic breast cancer. By flow cytometry, CXCR3 was detected in all murine mammary tumor cell lines examined. All human breast cancer cell lines examined also expressed CXCR3, as did the immortalized but nontumorigenic MCF-10A cell line. Interaction of CXCR3 ligands, CXCL9, CXCL10, and CXCL11, with CXCR3 on the highly malignant murine mammary tumor cell line 66.1 resulted in intracellular calcium mobilization and chemotaxis in vitro. To test the hypothesis that tumor metastasis is facilitated by CXCR3 expressed by tumor cells, we employed a small molecular weight antagonist of CXCR3, AMG487. 66.1 tumor cells were pretreated with AMG487 prior to i.v. injection into immune-competent female mice. Antagonism of CXCR3 on 66.1 tumor cells inhibited experimental lung metastasis, and this antimetastatic activity was compromised in mice depleted of natural killer cells. Systemic administration of AMG487 also inhibited experimental lung metastasis. In contrast to the antimetastatic effect of AMG487, local growth of 66.1 mammary tumors was not affected by receptor antagonism. These studies indicate that murine mammary tumor cells express CXCR3 which facilitates the development of lung metastases. These studies also indicate for the first time that a small molecular weight antagonist of CXCR3 has the potential to inhibit tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885372     DOI: 10.1158/0008-5472.CAN-06-0709

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  90 in total

1.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

2.  Potential role of CXCR3 in proliferation and invasion of prostate cancer cells.

Authors:  Daqing Shen; Xianxiang Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.

Authors:  Álvaro de Mingo Pulido; Alycia Gardner; Shandi Hiebler; Hatem Soliman; Hope S Rugo; Matthew F Krummel; Lisa M Coussens; Brian Ruffell
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

Review 4.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

5.  CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis.

Authors:  Teresina Laragione; Max Brenner; Barbara Sherry; Pércio S Gulko
Journal:  Arthritis Rheum       Date:  2011-11

6.  Roles for aberrant CXCR3 signaling in basal cell carcinoma: a case for dual activity.

Authors:  Yanlin Yu; Glenn Merlino
Journal:  Am J Pathol       Date:  2010-02-25       Impact factor: 4.307

7.  A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis.

Authors:  Z Xiang; Z-J Zhou; G-K Xia; X-H Zhang; Z-W Wei; J-T Zhu; J Yu; W Chen; Y He; R E Schwarz; R A Brekken; N Awasthi; C-H Zhang
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

8.  Chemokine receptor CXCR3 promotes growth of glioma.

Authors:  Che Liu; Defang Luo; Brent A Reynolds; Geeta Meher; Alan R Katritzky; Bao Lu; Craig J Gerard; Cyrus P Bhadha; Jeffrey K Harrison
Journal:  Carcinogenesis       Date:  2010-11-03       Impact factor: 4.944

9.  A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG.

Authors:  Ricardo J Flores; Aaron J Kelly; Yiting Li; Manjula Nakka; Donald A Barkauskas; Mark Krailo; Lisa L Wang; Laszlo Perlaky; Ching C Lau; M John Hicks; Tsz-Kwong Man
Journal:  Cancer       Date:  2016-08-16       Impact factor: 6.860

Review 10.  The chemokine receptors CXCR4 and CXCR3 in cancer.

Authors:  Amy M Fulton
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.